Volume 9, Winter 2013
Two men may have the same Gleason score, PSA , and clinical stage of cancer. But it's possible that one of them has a more aggressive tumor – one that is more likely to come back after surgery. That man, and his doctors, would give anything for this information up front. Scientist George Netto, M.D., is working to make that happen. With collaborators at the departments of Urology, Oncology and Pathology and the Bloomberg School of Public Health, he has been evaluating the role of a new potential prognostic biomarker, called PTEN, in prostate cancer.
To receive news and updates from the Brady Institute via email, please send your name and email address to email@example.com